Challenges and guiding principles of a national coordination of actors involved in producing, implementing and evaluating clinical guidelines for patients with cancer (in part I: What Cancer Plans have brought to the improvement of professional practices) [Enjeux et principes d’une coordination nationale des acteurs pour la production, l’implémentation et l’évaluation des outils d’aides à la décision médicale en cancérologie (in partie I : Les apports des Plans cancer au service de l’amélioration des pratiques professionnelles)]
Mazeau-Woynar V.,Institute National du Cancer
Oncologie | Year: 2014
In oncology, a large number of actors are involved in clinical guidelines development at the local or national level. This attests the need for decision-making tools, in the context of rapidly evolving knowledge and practices. However, the multiplicity of available guidelines, their redundancy and sometimes their divergence, questions the efficiency of the current scheme and the risks of disparity in terms of patient care. To address these issues, the new Cancer Plan entrusts to INCa the responsibility for coordinating actors at a national level in the production, implementation and evaluation of the impact of those tools. © 2014, Springer-Verlag France.
Key contributions of French Cancer Plans in professional practices improvement in oncogeriatrics — Institutional point of view (in part I: What Cancer Plans have brought to the improvement of professional practices) [L’organisation spécifique en oncogériatrie, le point de vue institutionnel (in partie I : Les apports des Plans cancer au service de l’amélioration des pratiques professionnelles)]
Brechot J.-M.,Institute National du Cancer
Oncologie | Year: 2014
Following a pilot phase during the first French Cancer Plan, a national roll-out of a specific organization for elderly people with cancer took place in the second Cancer Plan, to ensure every elderly with cancer access to an appropriate care. Two actions of the third Cancer Plan are dedicated to oncogeriatrics, one to support research, the other the training in geriatrics for oncologists. © 2014, Springer-Verlag France.
The French National Cancer Institute (INCa): an institute dedicated to a strong and lasting action in the fight against this disease [L’Institut national du cancer : un institut dédié au cancer pour garantir une impulsion forte et continue de la lutte contre cette maladie]
Burstin A.,Institute National du Cancer
Oncologie | Year: 2014
The French National Cancer Institute (INCa) is the preeminent health and science agency in charge of cancer control. Created under the Public Health Act of 2004, the French National Cancer Institute is an original and unique model among State agencies and at international level; it covers all modes of action to fight against the disease: research, observation and evaluation, prevention and screening, care organization and public information. The Institutes’ work is based on coordinating and integrating all intervention programmes. This coordination is a major mission of INCa and translates in its status of public interest group: it gathers all key stakeholders -charities, public sector, professional, industries- and favours constant exchanges. Along with the integration of all aspects of the fight against cancer, they warrants the expertise and relevance of INCa-driven actions. The inherent liability of an institute dedicated to the most deadly diseases in France is another key element that leads INCa to steer the 2014–2019 Cancer Plan, in close collaboration with the Ministries for Health and Research. © 2014, Springer-Verlag France.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2009-2.1.1-2 | Award Amount: 13.88M | Year: 2010
All cancers arise due to somatically acquired mutations in their genomes which alter the function of key cancer genes. Understanding these critical mutational events underlying cancer development is paramount for advancing prevention, early detection, monitoring and treatment of the disease. Breast cancer is the most common class of cancer diagnosed in women worldwide with more than one million cases diagnosed annually. It is responsible for >400,000 deaths per year making it the leading cause of cancer deaths in women and is the most common cause of all deaths in women aged >40yrs. Breast cancer is a heterogeneous disease with a number of subtypes. We propose here to generate complete catalogues of somatic mutations in 500 breast cancers, of the ER\ve HER2- subclass, under the International Cancer Genome Consortium model by high coverage, shotgun genome sequencing of both tumour and normal DNA. All classes of mutations are expected to be detected including base substitutions, insertions, deletions, copy number changes and rearrangements. These catalogues of mutations will afford us statistical power to identify cancer genes that are mutated at a frequency of greater than 3% in this class of breast cancer. Complementary catalogues of epigenomic changes (genome-wide DNA methylation) will be generated for the same cancer samples together with transcript expression profiles. Integrated analyses of these data will be carried out and compared to parallel datasets from other classes of breast cancer and other types of cancer. The potential clinical utility of these findings for detection and monitoring of minimal residual disease will be investigated. Finally, data will be made rapidly available to all scientific researchers with minimal restrictions. The results of this exhaustive and comprehensive set of studies will have an enormous impact on our understanding of the causes and biology of breast cancer and will lead to major advances in detection, prevention and treatment of breast cancer
Agency: Cordis | Branch: FP7 | Program: CSA-SA | Phase: HEALTH.2013.4.1-4 | Award Amount: 645.12K | Year: 2013
The Health Directorate of the European Commissions DG Research and Innovation recently stated that Personalized Medicine is one of the most innovative areas in the future of health research with a high potential for patients, citizens and the economy. However, today the full potential can not be developed due to fragmented activities, insufficient communication and lack of generic solutions in the different areas of Personalized Medicine.The implementation of Personalized Medicine is, therefore, a major challenge in Europe and beyond. It calls for appropriate governance strategies at the European and global level as it challenges the way in which healthcare systems worldwide are set up. Thus, the EC itself, EuroBioForum, the European Health Forum Gastein (EHFG) and others have organized conferences to tackle these challenges. Furthermore, key European organizations and institutions have come up with reports, guidelines, roadmaps aiming to give guidance in this emerging and important health research field amongst others the European Science Foundation (ESF) Forward Look, the Manifesto of the European Alliance for Personalised Medicine (EAPM), the European Best Practice Guidelines of the Public Health Genomics European Network (PHGEN), the Roche report on Personalized Medicine or the report of the European Hospital and Healthcare Federation (HOPE). Based on these initiatives European and national decision-makers and funding bodies not only have expressed the urgent need for a CSA, but also initiated this specific CSA to step up coordination efforts between the European key stakeholders to allow synergies and avoid duplication or competition, to ensure maximum transparency and openness preparing Europe for leading the global way.